UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Subependymal giant cell astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I trial study will evaluate the dosage, safety and efficacy of trametinib and everolimus in treating pediatric and young adult patients with recurrent low-grade glioma.
Conditions
Glioma
Glioblastoma
This is a phase 1/2a study to assess the safety, dose-limiting toxicities, recommended Phase 2 schedule, and preliminary efficacy of aminolevulinic acid sonodynamic therapy in patients with recurrent or progressive GBM.
Conditions
Glioblastoma
This multicenter phase 2 immunotherapy trial will evaluate the combination of two immune checkpoint inhibitors, nivolumab and relatlimab, in patients with newly diagnosed isocitrate dehydrogenase (IDH)-wild-type glioblastoma.
Conditions
Glioma
Glioblastoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This is a phase 1 immunotherapy trial for patients with recurrent high-grade gliomas designed to evaluate the safety and biological activity of the gene therapy, SRN-101, administered prior to planned surgical resection.
Conditions
Neurofibromatosis type 1
Glioma
Glioblastoma
This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with high-grade gliomas harboring mutations in the tumor suppressor gene NF1.
Conditions
Neurofibroma
Neurofibromatosis type 1
This phase 2 clinical trial will determine whether participants with asymptomatic plexiform neurofibromas in high-risk locations can potentially benefit from early treatment with selumetinib.
Conditions
Glioma
Glioblastoma
This is a phase 0/I exploratory study to evaluate the safety and toxicity profile of anti-TIGIT AB154 in combination with anti-PD-1 AB122 in patients with recurrent glioblastoma.
Conditions
Glioma
Glioblastoma
This single-center Phase I/Ib study in recurrent glioblastoma (GBM) aims to establish a recommended phase 2 dose of the mTOR inhibitor RMC-552 in GBM participants as well as to evaluate safety and antitumor effect of this drug.
Conditions
Glioblastoma
Glioma
This is an open-label phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of the drug TNG908 in patients with MTAP-deleted advanced or metastatic solid tumors.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
Neurofibromatosis type 1
This phase III clinical trial will compare the efficacy of selumetinib compared to standard treatment with carboplatin/vincristine (CV) in patients with NF1-associated low-grade glioma (LGG).
Conditions
Glioma
Glioblastoma
Astrocytoma
Oligodendroglioma
This is an international, open-label phase II clinical trial for recurrent patients who have a glioma harboring a BRAF abnormality.
Conditions
Glioma
Glioblastoma
This is a first-in-human phase 1 study to assess the safety and feasibility of using an IV infusion of E-SYNC T cells to treat patients with EGFRvIII-mutated glioblastoma (GBM).